Cyclosporine A Loaded PLGA Nanoparticles for Dry Eye Disease: <i>In Vitro</i> Characterization Studies

<table>Response surface plots for the <i>A</i> and <i>B</i> on particle size (<svg height="15.25" id="M36" style="vertical-align:-3.276pt" version="1.1" viewbox="0 0 19.924999 15.25" width="19.924999" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,11.112)"><path d="M775 650l-6 -28q-60 -6 -81.5 -16t-61.5 -54l-175 -191l125 -243q30 -58 48.5 -71t82.5 -19l-5 -28h-275l7 28l35 4q31 4 37 12t-6 34l-108 216q-140 -165 -177 -219q-16 -22 -10.5 -30.5t41.5 -13.5l22 -3l-7 -28h-244l8 28q52 4 75 15.5t67 52.5q48 46 206 231
l-110 215q-26 51 -44 63t-72 17l6 28h250l-6 -28l-27 -4q-30 -5 -35 -10t3 -27q17 -43 95 -190q70 78 154 185q15 21 10 29.5t-33 12.5l-30 4l5 28h236z" id="x1D44B"></path></g>
<g transform="matrix(.012,-0,0,-.012,13.525,15.187)"><path d="M384 0h-275v27q67 5 81.5 18.5t14.5 68.5v385q0 38 -7.5 47.5t-40.5 10.5l-48 2v24q85 15 178 52v-521q0 -55 14.5 -68.5t82.5 -18.5v-27z" id="x31"></path></g>
</svg>), where <i>A</i> = PLGA concentration and <i>B</i> = Eudragit RL100 concentration<b>.</b></table>

Journal of Nanotechnology

fig1

Figure 1

Figure 1: Cyclosporine A Loaded PLGA Nanoparticles for Dry Eye Disease: <i>In Vitro</i> Characterization Studies 

Journal of Nanotechnology

Cyclosporine A Loaded PLGA Nanoparticles for Dry Eye Disease: In Vitro Characterization Studies

Figure 1